Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Acq. announced
Director departure
Quarterly results
CC transcript
|
|
BIO REFERENCE LABORATORIES INC (BRLI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/19/2021 |
GN
| Brilliant Acquisition Corporation: New SEC Guidance Relating to SPAC Warrants, Its Effect on the Company's Periodic Filings and Compliance with Nasdaq Rules |
| 07/20/2020 |
GN
| Brilliant Acquisition Corporation Announces Separate Trading of its Ordinary Shares, Rights, and Warrants, Commencing July 22, 2020 |
| 06/30/2020 |
GN
| Brilliant Acquisition Corporation Announces Full Exercise of Overallotment Option |
| 06/26/2020 |
GN
| Brilliant Acquisition Corporation Announces Closing of $40 Million Initial Public Offering |
| 06/23/2020 |
GN
| BRILLIANT ACQUISITION CORPORATION ANNOUNCES PRICING OF $40 MILLION INITIAL PUBLIC OFFERING |
| 08/20/2015 |
8-K
| Quarterly results |
| 08/19/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 08/10/2015 |
8-K
| Other Events |
| 08/06/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 07/30/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 07/17/2015 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 07/02/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 07/02/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 06/18/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 06/11/2015 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 06/11/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 06/10/2015 |
8-K
| Investor presentation |
| 06/10/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 06/10/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 06/08/2015 |
10-Q
| Quarterly Report for the period ended April 30, 2015 |
| 06/08/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 06/08/2015 |
8-K
| Other Events, Financial Statements and Exhibits |
| 06/08/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 06/08/2015 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 06/04/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 06/04/2015 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Agreement and Plan of Merger among Bio-Reference Laboratories, Inc., OPKO Health, Inc. and Bamboo Acquisition, Inc",
"Employment Agreement among Bio-Reference Laboratories, Inc., OPKO Health, Inc. and Marc D. Grodman",
"Employment Agreement between Bio-Reference Laboratories, Inc. and Nicholas Papazicos",
"Ehxibit 99.1 OPKO Health to Acquire Bio-Reference Laboratories" |
|
| 06/04/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 06/04/2015 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 05/20/2015 |
8-K
| Entry into a Material Definitive Agreement |
| 04/29/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/13/2015 |
8-K
| Other Events |
| 03/09/2015 |
10-Q
| Quarterly Report for the period ended January 31, 2015 |
| 03/05/2015 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/05/2015 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended January 31, January 31, 2015 2014 Net Revenues $ 208,833 $ 181,270 Cost of Sales 119,078 109,116 Gross Profit on Revenues 89,755 72,154 General and Administrative 77,827 66,274 Operating Income 11,928 5,880 Other Expense, Net 424 625 Income Before Taxes 11,504 5,255 Taxes 4,871 2,301 Net Income 6,633 2,954 Income Per Share $ 0.24 $ 0.11 Number of Shares 27,740,309 27,700,167 Income Per Share $ 0.24 $ 0.11 Number of Shares 27,867,214 27,848,492 Bio-Reference Laboratories, Inc. Balance Sheets / Audited January 31, October 31, 2015 2014 Cash & Cash Equivalents $ 22,240 $ 17,507 Accounts Receivable 268,720 263,346 Plant, Property & Equipment 65,642 66,388 Intangible Assets 49,110 49,588 Other Assets 82,431 82,034 Total $ 488,143 $ 478,863 Accounts Payable $ 68,030 $ 71,166 ..." |
|
|
|
|